U.S. Markets open in 2 hrs.

Recro Pharma, Inc. (REPH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.25-0.23 (-2.71%)
At close: 4:00PM EDT
People also watch

Recro Pharma, Inc.

490 Lapp Road
Malvern, PA 19355
United States

Full Time Employees195

Key Executives

Dr. Geraldine A. Henwood Ph.D.Chief Exec. Officer and Pres933.38kN/A65
Mr. Michael Celano CPAChief Financial Officer343.58kN/A58
Mr. Frederick H. GraffChief Commercial Officer557.07kN/A67
Ms. Donna M. C. NicholsChief Accounting Officer, VP and Corp. ControllerN/AN/A61
Mr. Randall J. MackSr. VP of Devel. and Corp. Sec.N/AN/A52
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. Its lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. The company also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain. It also provides contract development and manufacturing services. It has a license agreement with Orion Corporation for the development and commercialization of Non-Injectable Dexmedetomidine. The company focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

Corporate Governance

Recro Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.